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Specialty Update

What’s New in Spine Surgery
Keith H. Bridwell, MD, Paul A. Anderson, MD, Scott D. Boden, MD, Han Jo Kim, MD,
Alexander R. Vaccaro, MD, PhD, and Jeffrey C. Wang, MD

What’s New in the Treatment of the Cervical Spine
Clinical spinal research has excelled in the past year, and the
results will aid in decision making for our patients. A large
observational trial and a series of systematic reviews on cervical
myelopathy provide much-needed evidence regarding treatment
decisions. The measurement and understanding of cervical
spinal alignment as part of the overall spinal balance and its
correlation to pain and neurologic dysfunction is being critically
evaluated. Three new cervical artificial discs have been approved,
and long-term outcomes of already approved devices show
maintenance of good and excellent outcomes.
Cervical Myelopathy
Fehlings et al. reported on the one-year results of a multicenter
observational study of 222 patients with cervical myelopathy.
Significant improvement was seen in pain reduction, function,
gait, and quality of life after surgery. Three patients had
neurologic deterioration perioperatively, and two recovered
to their baseline status. The outcomes with regard to anterior
or posterior approach, after adjusting for baseline differences,
showed no statistical differences. In a multivariate analysis,
predictors of poor outcome were longer duration of symptoms,
poorer baseline function, the presence of psychological comorbidities, severe gait disorder, and older age.
The journal Spine recently published a focus issue on
cervical myelopathy. The authors used systematic reviews and,
when appropriate, made recommendations in accordance with
currently accepted standards. Those reviews indicated that 20%
to 60% of patients with symptomatic cervical myelopathy had
subsequent neurologic deterioration if the myelopathy was not
treated surgically. Chronic spinal cord compression can result in
chronic inflammation, cellular apoptosis, and microvascular
Specialty Update has been developed in collaboration with the Board of
Specialty Societies (BOS) of the American Academy of Orthopaedic Surgeons.

compromise, which are believed to be the biologic basis for
neural deterioration. Unfortunately, no effective nonoperative
treatment was identified.
In asymptomatic patients who had spinal cord compression, there was strong evidence that 8% at one year and
23% of patients at a median follow-up time of forty-four
months will develop symptomatic cervical myelopathy. There
were conflicting results with regard to the prediction of outcome based on the effect of cord signal changes. Asymptomatic
patients with clinical or electrophysiological evidence of
radicular dysfunction or central conduction deficits have an
increased risk of the development of symptomatic cervical
myelopathy. Imaging predictors of deterioration and surgical
outcome remain enigmatic. Only weak associations can be
found between the development of symptomatic cervical myelopathy and high signal on T2-weighted magnetic resonance
imaging (MRI), the number of levels compressed, the presence
of signal changes on T1-weighted and T2-weighted MRI, and
spinal cord compression ratios that exceed 50%. If T2-weighted
signal changes are to be used clinically, they should be used
in combination with other imaging parameters, such as compression ratio and the number of levels involved.
Sagittal Balance of the Cervical Spine
Sagittal balance of the cervical spine and its relation to overall
spinal alignment and neurologic syndromes is increasingly
being evaluated. It is known that scoliotic patients with thoracic
hypokyphosis have compensatory cervical kyphosis. Newer
thinking is that cervical malalignment should be assessed in
conjunction with thoracolumbar sacral pelvic alignment. Kyphosis can be evaluated with use of the C2-C7 Cobb angle or its
variants or by evaluation of sagittal alignment. The latter is best
performed with use of the C2-C7 sagittal vertical axis, measured as the horizontal distance between a plumb line from the
center of C2 and the posterior aspect of the C7 superior end
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What’s New in Spine Surgery
plate. Sagittal cervical malalignment can also be associated with
pain and myelopathy. In a study of fifty-six patients with cervical
myelopathy, sagittal alignment (as documented by C2-C7 sagittal
vertical axis but not kyphotic angle) correlated with myelopathic
symptoms. Further, increased C2-C7 sagittal vertical axis was
correlated with decreased cord volume and cross-sectional area,
while the opposite was true for lordotic alignment.
Disc Arthroplasty
In the last year, two additional total cervical disc replacement
devices have been approved by the U.S. Food and Drug Administration (FDA) for single-level radiculopathy or myelopathy while another was approved by the FDA for both single
level and two levels. These devices had similar outcomes and
safety profiles as the other already approved discs. Long-term
outcomes of currently approved devices at seven to nine years
after implantation show maintenance of good to excellent
clinical outcomes and, in general, lower reoperation rates at
adjacent levels as compared with the reoperation rates of
control patients who were managed with fusion. Explant
analyses of cervical discs have consistently shown pathologic
wear patterns secondary to edge impingement. However,
substantial inflammatory reactions, such as those seen in patients with metal-on-metal arthroplasty devices, are rare. Cost
analyses made with use of insurance databases show lower costs
after arthroplasty than after fusion, largely because of lower
reoperation rates and lower postoperative cost of care.
What’s New in Biologic Topics for the Spine
Much of the 2013 focus on biologics in the spine was centered
on the safety of recombinant human bone morphogenetic
proteins (rhBMPs). In addition, there were continued efforts to
find biologic treatments for disc degeneration.
Recombinant Osteoinductive Proteins
In 2013, there was a continued focus on the potential local
adverse events associated with rhBMP-2. Since 2011, questions
have been raised with regard to the association of INFUSE bone
graft (Medtronic) with retrograde ejaculation and cancer. In
June of 2013, the Yale University Open Data Access (YODA)
effort reported two independent assessments of raw data from
the Medtronic clinical trial database on INFUSE. One study
confirmed that fusion success was comparable with that
achieved with autograft, and the other study showed a slight
increase in fusion rates for the INFUSE group. Neither study
found a significant increase in retrograde ejaculation. One
study showed an increased risk of cancer at twenty-four but not
forty-eight months, while the authors of the other study believed
that the small number of cancer events precluded firm conclusions. Review of the FDA investigational device exemption data
regarding posterolateral higher dose (40 mg) rhBMP-2 showed
that there was a higher prevalence of cancer in patients who
received rhBMP-2 than there was in control patients, raising the
possibility of a dose effect. Since the time of publication of those

studies, a review of 146,000 Medicare patients (average 4.7-year
follow-up; 15.4% rhBMP patients versus 17.0% control patients
with detected new cancer) demonstrated no association of
rhBMP with cancer risk. While any actual association with
cancer remains unclear, the most likely potential mechanism of
tumor enhancement may be via induction of vascular endothelial growth factor or other factors that promote tumor survival, since rhBMP-2 biologically typically slows growth in the
majority of cancer cell lines.
The relative benefit and potential local side effects of
INFUSE are best reviewed with regard to the specific application. Use of INFUSE in anterior cervical spine fusion has been
associated with increased seromas and dysphagia. Recent work
has confirmed that these local side effects are dose-related. Use
of INFUSE in multilevel anterior cervical arthrodesis resulted
in higher fusion rates without complications when the dose did
not exceed 1.1 mg/level.
Anterior lumbar interbody fusion, the only ‘‘on-label’’
indication, has been associated with vertebral resorption and
graft subsidence. Recent studies suggest that these side effects
are related to dose (>6 mg/level) and possibly to aggressive
end-plate decortication.
Posterior or transforaminal lumbar interbody fusion
with INFUSE is associated with an increased prevalence of
postoperative radiculitis in some reports. Other reports demonstrate consistently high fusion rates (>90%) with low rates of
seroma (<0.4%) and ectopic bone (0.6%). This dichotomy
suggests that these local side effects are avoidable with proper
dosing and surgical technique.
Posterolateral spine fusion is the application that likely
affords the greatest opportunity for improvement of fusion
rates with use of iliac crest bone graft. The four-year follow-up
results of a Canadian study showed that fusion rates were
higher in the rhBMP-2 group (94%) than they were in the
group with autograft (69%). Another study added INFUSE to
local bone graft and demonstrated high (>95%) fusion rates.
The complication rate related to rhBMP-2 does not appear to
be any higher in patients who are sixty-five years or older than
it is in younger patients.
Spinal deformity in adults is another area in which the
use of INFUSE can result in a major improvement in fusion
success. In the first report of the use of a high-dose (40 to 351
mg) of INFUSE in adult multilevel posterolateral and interbody
fusions, the cancer prevalence rate was 3.4% and there was no
correlation to increased dose. There was also no dose correlation with radiculopathy (1%) or seroma (0.6%). A prospective
international study also reported no correlation between
rhBMP-2 use and complications in adult patients with spinal
deformity. In another report of long fusions to the sacrum, the
use of rhBMP reduced the nonunion rate from 28.1% to 6.4%,
and to 0% when >5 mg/level rhBMP-2 was used. Use of 20 mg
rhBMP-2 posterolaterally at the L5-S1 level can provide a comparable fusion rate at a lower cost than a combined interbody
fusion at that level.
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Other Bone-Graft Substitutes
Although much focus remains on rhBMPs, their relatively high
cost has continued to encourage research involving other bonegraft solutions. There is continued interest in bone marrow, and
studies show that the first 2 to 4 mL of aspirate from a vertebra is
optimal. The clinical effectiveness of marrow remains in question.
Biologic Treatments for Disc Degeneration
Progress toward biologic treatments to prevent or retard disc
degeneration continues. There is continued interest in the
anabolic effect of BMP-7, link protein peptide, and platelets.
Most of the studies in the past year have been in vitro proof-ofconcept studies, which are difficult to translate into organ
culture or the in vivo setting, making this a rewarding but
challenging area.
What’s New in Spinal Deformity Surgery
There were 129 papers presented from the podium and 105
posters presented at the Forty-eighth Annual Meeting of the
Scoliosis Research Society (SRS), which met from September
18 through 21, 2013, in Lyon, France.
Adolescent Idiopathic Scoliosis
Studies from the SRS member database reviewed more than
17,400 cases of adolescent idiopathic scoliosis and demonstrated that, compared with the operations performed a decade
previous to this writing, operations for adolescent idiopathic
scoliosis are currently being performed with fewer complications
and with an all-posterior approach. The decrease in complications may be attributed to the decrease in combined anteriorposterior approaches for these deformities as well as to the use of
pedicle screw instrumentation, which increased from 9.5% of
cases in 2002 to more than 50% in 2007.
Curve progression after treatment for adolescent idiopathic scoliosis continues to be a concern. At the time of the
five-year follow-up in one study, a 22% prevalence of distal
adding on was demonstrated after posterior spinal fusion for
adolescent idiopathic scoliosis, although this did not affect
clinical outcomes or revision surgery rates.
Dr. Stuart Weinstein reported the results of the National
Institutes of Health (NIH) Bracing in Adolescent Idiopathic
Scoliosis Trial (BrAIST), a prospective randomized, clinical
study of the efficacy of bracing for the treatment of adolescent
idiopathic scoliosis. In the short term, bracing was effective in
this study, and compliance over thirteen waking hours of the
day was recommended.
Adult Spinal Deformity
More than 7500 cases of surgically treated adult spinal deformity
were reviewed in a study of the SRS member database. Unlike
adolescent cases, these continue to have roughly equal combined
anterior-posterior and all-posterior approaches for management.
The combined anterior-posterior approach demonstrated higher
complication rates. Nonetheless, studies from the International

Spine Study Group demonstrated that operative treatment of
adult spinal deformity is cost-effective and results in superior
outcomes as compared with nonoperative treatment.
Use of rhBMP-2 in long fusions for the treatment of adult
scoliosis was a topic presented with much attention. In adult
deformity surgery, rhBMP-2 was associated with fewer complications in the long term and lower rates of revision surgery
due to implant failures at a minimum follow-up of two-years
when compared with cases in which no rhBMP-2 was used.
With regard to the possible risk of cancer, a study that was
presented at the 2013 SRS annual meeting and in which more
than 127,000 cases of rhBMP-2 use were reviewed demonstrated that age was the most important risk factor for the
development of cancer, whereas use of rhBMP-2 was not definitively related to cancer prevalence.
Important prospective data from one multicenter study on
adult deformity surgery demonstrated a 17% risk of neurologic
complications occurring as a result of adult deformity surgery.
Proximal junctional kyphosis continues to be a clinical
enigma, with three papers focused on this topic. Although
prior studies have demonstrated that sagittal balance corrections to 0 cm and high lumbar lordosis were associated with
good outcomes, data were presented that suggest that, for older
patients having deformity surgery, the patient should be allowed
to remain with a small amount of positive sagittal balance and to
have a more moderate restoration of lumbar lordosis to provide
a more natural global sagittal balance and possibly prevent
proximal junctional kyphosis.
In a randomized controlled trial, the use of antifibrinolytic
agents in adult deformity surgery resulted in lower intraoperative
blood loss as compared with that in control patients.
Neuromuscular Scoliosis
Infection continues to be an important concern in the surgical
management of neuromuscular scoliosis. Multiple studies
demonstrated lower infection rates in patients with neuromuscular scoliosis when topical vancomycin was placed in the wound
at the time of closure. No associated systemic complications were
reported using this technique.
Early Onset Scoliosis
Preliminary data on vertebral body stapling for the treatment of
early onset scoliosis were reported. However, the cohort was
small and the follow-up was short.
Basic Science
A number of centers continue to develop animal models for
idiopathic scoliosis. One study reproduced a juvenile-type scoliosis in mice with steroid receptor deficiency in chondrocytes.
However, this model seems to be more demonstrative of the
skeletal dysplasia type of scoliosis rather than idiopathic scoliosis.
Vitamin D continues to draw research interest, with an
animal study showing larger and more robust fusion masses in
vitamin-D-replete rats as compared with vitamin-D-deficient rats.
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What’s New in the Treatment of Spinal Cord Injury
Given the low prevalence of spinal cord injury and the rapid
rate of recovery within the first three months after injury, any
effort to demonstrate an effective intervention that improves
spinal cord recovery requires an extensive data set incorporating multiple centers and investigators.
Pharmacologic Neuroprotective Intervention
Riluzole, a benzothiazole anticonvulsant sodium-channel
blocking agent that has FDA approval for use in amyotrophic
lateral sclerosis, has recently completed a prospective, multicenter
phase-1 study looking at the efficacy, pharmacokinetics, and safety
of its use in the treatment of patients with spinal cord injury.
Riluzole binds and blocks voltage-gated sodium channels, potentially mitigating against excitotoxic neural damage
as well as blocking presynaptic calcium-dependent glutamate
release, a mechanism known to be involved in secondary injury
to the spinal cord. Data from the North American Clinical
Trials Network (NACTN) spinal cord injury registry revealed
that patients who were given 50 mg riluzole by mouth or via
nasogastric tube twice daily for fourteen days, starting within
twelve hours after cervical spinal cord injury, were noted to
have a 31.2-point increase in mean motor score at ninety days
after injury compared with a 15.7-point improvement in
matched NACTN-registry patients who received no riluzole.
In an effort to improve neurologic outcome in patients
who have sustained an acute, complete spinal cord injury, a
phase-2 randomized controlled multicenter trial using sitespecific injection of macrophages was performed. Autologous
incubated macrophages were injected into the caudal boundary
of the spinal cord injury. During the six-month follow-up
period, neurologic improvement from grade A to grade B of the
American Spinal Injury Association (ASIA) Impairment Scale
(AIS) was experienced in only seven of twenty-six treatment
patients, whereas improvement occurred in ten of seventeen
control patients. Improvement from AIS grade A to grade C
occurred in two treatment and two control patients. Overall,
there was a trend favoring the control group for the primary
outcome measure.
Pharmacologic Neuroregenerative Intervention
Results of a phase-1/2a clinical trial of BA-210 (trademarked as
Cethrin by BioAxone Biosciences), a Rho pathway antagonist,
were recently reported. A multicenter study enrolled fortyeight AIS grade-A cervical (C4-T1) and thoracic (T2-T12)
spinal-cord-injured patients and followed them for one year
after the injury. A single dose of Cethrin combined with a fibrin
sealant was applied directly to the dura mater following a decompression. The dose ranged from 0.3 to 9 mg. The largest
observed change in motor score occurred in the 3-mg-dose
group, with 6% of the thoracic patients improving from AIS
grade A to C or D as compared with 33% of cervical patients.
The small number of study participants in this study renders
efficacy somewhat difficult to interpret.

As recently as June 2013, minocycline was entered into a
phase-3 clinical trial examining the efficacy of intravenous
minocycline treatment compared with placebo in nonpenetrating spinal cord injury. The phase-2 study, recently
presented, demonstrated marked recovery in patients who had
been managed with minocycline in the cervical spinal cord
injury group, whereas the thoracic group demonstrated no
benefit. Mean ASIA motor score improvement in the cervical
group was 14 points over controls at the time of the final
follow-up (p = 0.05).
On January 23, 2013, physicians of the Miami Project to
Cure Paralysis successfully performed the first Schwann-cell
transplantation in a patient with new spinal cord injury. This
surgery was part of an FDA-approved phase-1 clinical trial
evaluating the safety and efficacy of autologous Schwann-cell
transplantation into patients with spinal cord injury. The study
patients will be followed for twelve months after transplantation. The olfactory mucosa comprises neurosensory cells that
are continuously renewed throughout life. A prime component
of the olfactory mucosa, the olfactory ensheathing cells are
pluripotent stem cells exhibiting Schwann-cell-like properties
that function within the olfactory mucosa to guide growth of
axons from mucosal neurons to the olfactory bulb. Olfactory
ensheathing cells can be obtained from either the olfactory
mucosa or from cells of the olfactory bulb, which exists above
the cribriform plate of the ethmoid bone at the base of the
brain. Despite the fact that olfactory mucosa cells require a
purification process that is unnecessary with olfactory bulb
cells, on the basis of a recent risk-to-benefit analysis of the use
of olfactory mucosa cells and olfactory bulb cells, the process to
obtain olfactory mucosa cells is associated with much less
morbidity, resulting in a much better risk-to-benefit ratio.
What’s New in the Treatment of the Lumbar Spine
Pathologies leading to lumbar spinal disorders continue to be one
of the most common clinical problems faced by spine practitioners.
Over the past year, there have been a number of research studies
that have given an update on some of these specific problems.
Reduction of Blood Loss
Authors presented a study looking at the use of antifibrinolytic
agents such as tranexamic acid and aminocaproic acid in patients
undergoing long posterior spinal fusion for the treatment of adult
deformity. This was a prospective double-blinded study of patients receiving either tranexamic acid (nineteen patients), aminocaproic acid (nineteen patients), or placebo (fourteen patients)
in the operating room (mean ages: sixty, forty-seven, and fortyfive years, respectively). For patients who were fifty years or older,
intraoperative blood loss in both the tranexamic acid and aminocaproic acid groups was less than that seen in the control
group, although there was no significant difference for patients
who were younger than fifty years. There was also a significantly
lower postoperative transfusion rate between aminocaproic acid
and placebo groups. One patient in each treatment arm was
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What’s New in Spine Surgery
diagnosed with a pulmonary embolism. The findings support the
use of these antifibrinolytic agents in adult deformity surgery in
patients who are older than fifty years.
Nonoperative Management
The effect of nonoperative treatment continues to be of interest. Utilizing a prospective registry, one group of authors
performed a comparative effectiveness and cost-utility analysis
comparing surgical and nonsurgical medical management in
elderly patients with surgical degenerative disorders. Ninety-five
elderly patients (i.e., older than sixty-five years) with degenerative
lumbar spondylosis conditions (stenosis, spondylolisthesis, or disc
herniation) had surgery and were entered into a prospective
registry. Both surgical and nonsurgical treatments were tracked at
a single institution. Of the ninety-five patients, fifty had surgical
treatments while forty-five had only nonsurgical medical management. Surgical management demonstrated a significant twoyear improvement in all clinical validated outcome measures,
while nonsurgical management failed to provide any significant
improvement in any measure (visual analog scale, Oswestry
Disability Index, EuroQol 5D, or quality-adjusted life years). The
two-year gain in quality-adjusted life years was significantly
greater after surgical management (0.67 quality-adjusted life years
gained) than after nonsurgical medical management (0.18 qualityadjusted life year gained). Total cost over the two-year period
was significantly greater for surgical management ($41,500) than
for nonsurgical management ($14,000), and cost per qualityadjusted life year gained for surgical management versus nonsurgical management was $56,437. From a value-based purchasing
and patient-centered perspective, prolonged nonsurgical medical
management is an inferior treatment option in the elderly population with these surgical degenerative lumbar disorders.
Low Back Pain
Low back pain remains a major clinical problem. One group of
authors examined the inter-relationships between physical
activity, obesity, and low back pain. This was a cross-sectional
population-based study of 6796 adults from the 2003 to 2004
National Health and Nutrition Examination Survey of the
National Center for Health Statistics of the U.S. Department of
Health and Human Services Centers for Disease Control and
Prevention. The authors found that the risk of low back pain
increases in a step-wise fashion with body mass index (BMI),
from 2.9% for normal weight (BMI = 20 to 25 kg/m2), to 5.2%
for overweight (BMI = 26 to 30 kg/m2), to 7.7% for obese
(BMI = 31 to 35 kg/m2), and 11.6% for ultra-obese (BMI = 36
kg/m2 or higher). Smoking was the strongest predictor of low
back pain across the BMI spectrum, while physical activity
decreases all of these risks. The role of physical activity to
decrease the risk of low back pain is of the highest consequence
in overweight and obese populations.
Another group of authors examined the prevalence of
first-time low back pain and correlated this with MRI findings.
This was a prospective radiographic and clinical study of 248

asymptomatic patients with no previous history of low back
pain. All these subjects underwent MRI studies of the lumbar
spine. These patients were followed for a minimum of two
years and were clinically assessed for the development of
symptoms, which were then correlated to baseline MRI
findings. The overall presence of disc degeneration, discspace narrowing, and disc bulging and/or extrusions were
noted in 60.5%, 19.0%, and 34.3% of the population, respectively. The mean clinical follow-up period was 4.3 years.
The prevalence rate of first-time low back pain episodes on
clinical follow-up was 34.7%, and the mean age of the patients at the time of a first-time low back pain episode was
44.8 years. The presence of disc bulging and/or extrusion and
increasing degenerative disc disease score (particularly in the
mid lumbar spine) were significant predictors for the development of a first-time low back pain episode. Degenerative disc disease severity and disc bulging and/or extrusion
were predictive of the severity of low back pain, greater
functional disability, and increased frequency of future episodes of low back pain.
Return to Driving
A group of authors examined the return of driver reaction time
to assess when patients could return to driving following
lumbar and cervical surgery. This was a prospective study of
thirty-seven patients with use of a computer software program
to mimic driving a car. Patients were tested prior to surgery and
retested postoperatively to see when they returned to their
baseline score. The authors concluded that these patients
could consider resuming driving two to three weeks following spinal surgery, provided that they were not taking
narcotics and they had no other impairments that would
deter them from driving.
Appendix: Evidence-Based Orthopaedics
The editorial staff of The Journal reviewed a large number of
recently published research studies related to the musculoskeletal system that received a Level of Evidence grade of I or II.
More than 100 medical journals were reviewed to identify these
articles, which all have high-quality study design. In addition to
articles published previously in this journal or cited already in
the Update, fifty-one additional Level-I and II studies were
identified that were relevant to spine surgery. A list of those
titles is available with the online version of this article as a data
supplement at jbjs.org. We have provided a brief commentary
about each of the articles to help to guide your further
reading, in an evidence-based fashion, in this subspecialty
area.
Upcoming Meetings and Events Related to Spine
Surgery
 The Scoliosis Research Society (SRS) Forty-ninth
Annual Meeting will be held September 10 through 13,
2014, in Anchorage, Alaska. Web site: www.srs.org
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EUROSPINE Annual Meeting will be held October
1 through 3, 2014, in Lyon, France. Web site:
www.eurospine.org
The North American Spine Society (NASS) Twentyninth Annual Meeting will be held November 12
through 15, 2014, in San Francisco, California. Web
site: www.spine.org
The Cervical Spine Research Society (CSRS) Fortysecond Annual Meeting will be held December 4
through 6, 2014, in Orlando, Florida. Web site:
www.csrs.org
The AANS/CNS (American Association of Neurological Surgeons/Congress of Neurological Surgeons)
Section on Disorders of the Spine and Peripheral
Nerves Annual Meeting will be held March 4 through
7, 2015, in Phoenix, Arizona. Web site: http://
spinesection.org
The Federation of Spine Associations will present the
spine program at Specialty Day at the Annual Meeting
of the American Academy of Orthopaedic Surgeons
(AAOS) on March 28, 2015, in Las Vegas, Nevada. Web
site: www.aaos.org
The International Society for the Advancement of
Spine Surgery (ISASS) Fifteenth Annual Meeting will
be held April 14 through 17, 2015, in San Diego,
California. Web site: www.isass.org
The American Spinal Injury Association (ASIA) Fortysecond Annual Meeting will be held on May 14 and 15,
2015, in Montreal, Quebec, Canada. Web site: www.asiaspinalinjury.org
The International Society for the Study of the Lumbar
Spine (ISSLS) Forty-second Annual Meeting will be
held June 8 through 12, 2015, in San Francisco,
California. Web site: www.issls.org
The International Meeting on Advanced Spine
Techniques (IMAST) Twenty-second Annual
Meeting will be held July 8 through 11, 2015, in
Kuala Lumpur, Malaysia. Web site: www.srs.org/
meetings
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